Vanguard Group Inc. reduced its stake in Sotera Health Company (NASDAQ:SHC – Free Report) by 0.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 14,897,175 shares of the company’s stock after selling 26,371 shares during the quarter. Vanguard Group Inc. owned 5.25% of Sotera Health worth $173,701,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in SHC. Quarry LP purchased a new position in Sotera Health during the 4th quarter valued at about $28,000. Farther Finance Advisors LLC increased its stake in Sotera Health by 4,881.9% during the first quarter. Farther Finance Advisors LLC now owns 6,327 shares of the company’s stock worth $70,000 after purchasing an additional 6,200 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Sotera Health by 37.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company’s stock worth $82,000 after purchasing an additional 1,640 shares in the last quarter. Sterling Capital Management LLC boosted its stake in shares of Sotera Health by 58.5% in the fourth quarter. Sterling Capital Management LLC now owns 9,029 shares of the company’s stock valued at $124,000 after purchasing an additional 3,331 shares during the period. Finally, Corton Capital Inc. purchased a new position in shares of Sotera Health in the fourth quarter valued at approximately $139,000. Institutional investors and hedge funds own 91.03% of the company’s stock.
Sotera Health Stock Performance
Shares of Sotera Health stock opened at $16.30 on Thursday. Sotera Health Company has a one year low of $9.53 and a one year high of $17.08. The company has a market cap of $4.63 billion, a PE ratio of 203.78 and a beta of 1.81. The company has a debt-to-equity ratio of 4.49, a quick ratio of 2.23 and a current ratio of 2.47. The business has a 50-day simple moving average of $12.16 and a 200-day simple moving average of $12.14.
Wall Street Analyst Weigh In
Several research firms have commented on SHC. Piper Sandler dropped their price target on shares of Sotera Health from $15.00 to $13.00 and set a “neutral” rating for the company in a research note on Wednesday, April 23rd. The Goldman Sachs Group upgraded Sotera Health from a “neutral” rating to a “buy” rating and increased their price objective for the company from $14.00 to $17.00 in a research note on Monday, May 5th. Wall Street Zen raised Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Finally, Barclays restated an “overweight” rating on shares of Sotera Health in a report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Sotera Health currently has an average rating of “Moderate Buy” and a consensus target price of $16.00.
Check Out Our Latest Report on SHC
About Sotera Health
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Further Reading
- Five stocks we like better than Sotera Health
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Lowe’s Builds Value for Investors: Still a Good Buy in 2025
- How to invest in marijuana stocks in 7 steps
- Jackson Hole 2025: Fed’s Signal Could Shift Stocks Fast
- How to Use the MarketBeat Dividend Calculator
- Rocket Lab Stock: Breakout Brewing or Time for Patience?
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.